Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
April 29, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in Phase 2 studySystemic...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
March 12, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public offering in February...
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
December 09, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
November 04, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET - Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:...
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
October 03, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU...
Emerald Health Therapeutics Joint Venture Launches Cannabis-Free Endocannabinoid-Supporting Health Supplement in Canada
July 02, 2019 07:00 ET
|
Emerald Health Therapeutics Inc.
VANCOUVER, British Columbia, July 02, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), through its joint venture Emerald Health Naturals (“EHN”), has...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
May 29, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 29, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 02, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company anticipates topline results of RESOLVE-1 study in the summer of 2020Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S.,...
Linkreservations Inc. announces new LinkResPet CBD product designed for horses
March 11, 2019 07:00 ET
|
Linkreservations Inc.
LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Linkreservations Inc. (OTC: LRSV), a company providing cannabidiol (CBD) products especially tailored for pets, announces the launch of a new CBD product...
Emerald Health Therapeutics’ Licensed Endo Product Wins Taste For Life’s 2019 Essentials Supplement Award in the U.S.
March 07, 2019 07:00 ET
|
Emerald Health Therapeutics Inc.
SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today announced that its joint venture partner’s, (Emerald Health Bioceuticals or...